InVitae's 211-Gene Test in Early Access as It Aims for Sub-$1,000 Test for 1,000 Disorders | GenomeWeb

Genetic testing company InVitae said last week that its 211-gene sequencing-based assay that screens for just over 260 genetic conditions is now being offered to early-access customers.

In a presentation at Cambridge Healthtech Institute's Clinical Genome Conference in San Francisco last week, CEO Randy Scott said that the company is working with 20 to 30 early-access physicians.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.